Chester County News and Community Website
WILMINGTON, DE — New data from the BaxHTN Phase III trial indicate that baxdrostat, an investigational aldosterone synthase inhibitor, achieved significant reductions in systolic blood pressure among patients with uncontrolled …
Phase III Trial Shows Baxdrostat Significantly Lowers Blood Pressure in Hard-to-Treat Hypertension Read More
WILMINGTON, DE — AstraZeneca has introduced FluMist Home, a first-of-its-kind at-home delivery and self-administration service for its nasal spray flu vaccine, FLUMIST® (Influenza Vaccine Live, Intranasal). The new option allows …
AstraZeneca Launches First At-Home Influenza Vaccine Service With FluMist Home Read More WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in the treatment of …
AstraZeneca’s IMFINZI® Granted Priority Review for Early-Stage Gastric Cancer Treatment Read More WILMINGTON, DE — AstraZeneca has announced a sweeping $50 billion investment across the United States through 2030, marking the company’s largest commitment to U.S. pharmaceutical operations to date. The move signals …
AstraZeneca Unveils $50 Billion U.S. Investment Plan, Anchored by Massive Virginia Manufacturing Site Read More WILMINGTON, DE — AstraZeneca announced that its lung cancer therapy TAGRISSO® (osimertinib), when used in combination with chemotherapy, delivered a statistically significant and clinically meaningful improvement in overall survival for patients …
AstraZeneca’s TAGRISSO Combo Shows Strong Survival Benefit in EGFR-Mutated Lung Cancer Read More WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has granted accelerated approval to DATROWAY® (datopotamab deruxtecan-dlnk) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated …
FDA Grants Accelerated Approval for DATROWAY in Advanced EGFR-Mutated Lung Cancer Read More WILMINGTON, DE — The Phase III DESTINY-Breast09 clinical trial has delivered groundbreaking results, demonstrating that ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab significantly improves progression-free survival (PFS) for patients with HER2-positive metastatic …
ENHERTU plus Pertuzumab Shows Significant Progress in First-Line Treatment for HER2-Positive Breast Cancer Read More WILMINGTON, DE — The Phase III MATTERHORN trial has delivered groundbreaking results, demonstrating that AstraZeneca’s IMFINZI® (durvalumab) combined with FLOT chemotherapy significantly improves outcomes for patients with resectable early-stage and …
MATTERHORN Trial Reveals Promising Results for Early Gastric Cancer Treatment Read More WILMINGTON, DE — Groundbreaking results from AstraZeneca’s Phase III SERENA-6 trial reveal a significant leap forward in the treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer. The trial demonstrated …
AstraZeneca’s SERENA-6 Trial Marks Breakthrough in Breast Cancer Treatment Read More WILMINGTON, DE — AstraZeneca is advancing its global efforts to transform cancer care by presenting pivotal data from its oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual …
AstraZeneca Showcases Oncology Breakthroughs Ahead of ASCO 2025 Read More